Familial Adenomatous Polyposis (FAP)
10
3
4
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
1 terminated out of 10 trials
66.7%
-19.9% vs benchmark
10%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (10)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL)
Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)
LATA-IBD TRIAL a Controlled Feasibility Study for the Introduction of Transanal Minimally Invasive IPAA-Surgery. Evaluation of Operative Results and Bowel Function After Introducing Transanal IPAA-surgery to Replace Conventional Laparoscopic IPAA-surgery.
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Preventive Anti-inflammatory Diet to Reduce Gastro-intestinal Inflammation in FAP Patients: a Prospective Pilot Study